Core Viewpoint - The company Jin Dawei is focusing on expanding its domestic market presence while maintaining strong overseas sales, particularly through its brand Doctor's Best, which has a significant portion of its sales from North America [1][3]. Group 1: Financial Performance - In the first half of 2025, Jin Dawei achieved a revenue of 1.728 billion yuan, representing a year-on-year growth of 13.46%, and a net profit of 247 million yuan, up 90.12% year-on-year [3]. - The overseas sales accounted for 1.302 billion yuan, making up 75.32% of total revenue, with a year-on-year growth of 5.89%, while domestic sales reached 427 million yuan, representing 24.68% of total revenue and a growth rate of 45.14% [1][3]. Group 2: Product Performance - The revenue from nutritional health products was 943 million yuan, accounting for 54.57% of total revenue, but experienced a year-on-year decline of 2.35% [3][4]. - The Coenzyme Q10 series generated 381 million yuan, making up 22.04% of total revenue, with a slight growth of 0.33% [3]. - The Vitamin A series saw significant growth, with revenue reaching 197 million yuan, accounting for 11.41% of total revenue, and a remarkable year-on-year increase of 213.06% [3][4]. Group 3: Market Strategy - Jin Dawei plans to enhance the sales efforts of Doctor's Best in the domestic market by leveraging new media channels and improving product quality and channel construction [1]. - The company is aware of the competitive pressures in the nutritional health food market and aims to strengthen its product development, brand value, and channel construction to maintain its market position [4]. Group 4: Future Outlook - The company expresses confidence in the future growth of its Coenzyme Q10 products, driven by increasing global demand due to aging populations and rising health awareness [7]. - Jin Dawei is expanding its production capacity and increasing exports to meet the growing demand, with production volume increasing by 37.50% and inventory levels rising by 100.12% [7].

Group 1: Company Operations and Market Position - The company is the largest producer of Coenzyme Q10 globally, recognized for its quality and production capacity, which is at the industry's leading level [2][3] - The company has undergone capacity expansion and transformation, significantly reducing production costs and increasing market share, thereby reinforcing its dominant market position [3] - Coenzyme Q10 is widely used in cardiovascular health and anti-aging sectors, with market demand expected to continue growing due to global aging and rising health awareness [3] Group 2: Product Development and Market Strategy - The company plans to closely monitor developments in the health and biosynthesis sectors, aligning R&D projects with market prospects and enhancing its synthetic biology research platform [2] - The company aims to strengthen its raw material supply chain and accelerate the industrialization of new products, focusing on biosynthesis research and global brand strategy [3] - The company is committed to building a strong brand presence in the health supplement market through a "big product + product matrix" strategy, leveraging both raw material and brand advantages [3] Group 3: Competitive Landscape - The U.S. dietary supplement market is highly fragmented, with the company focusing on maintaining its operational philosophy and differentiation to enhance market share for its star products [3] - The Doctor's Best brand emphasizes the use of high-quality raw materials and targets consumers interested in scientifically formulated nutrition, maintaining a leading position in the market [3]

Group 1: Overall Business Performance - In the first half of 2025, the company's total revenue reached 17.28 billion yuan, a 13.46% increase compared to the same period last year [2] - The net profit attributable to shareholders was 90.12 million yuan, reflecting a 2.47% growth year-on-year [2] Group 2: Nutritional Raw Materials Business - The company specializes in the large-scale production of products such as Coenzyme Q10, DHA, ARA, NMN, and Vitamin K2, among others [3] - Coenzyme Q10 holds the largest global market share, with a significant increase in gross margin due to production scale effects and technological improvements [3] - The company is investing in new product development using synthetic biology and microbial fermentation technologies [3] Group 3: Coenzyme Q10 Business - Coenzyme Q10 is increasingly recognized for its health benefits, leading to a growing market demand, particularly in China due to aging population and upgraded health awareness [3] - The company is the largest global producer of Coenzyme Q10, exporting to numerous countries and regions [3] - Expansion plans are in place to meet the rising market demand and strengthen the company's leading position in the industry [3] Group 4: Nutritional Supplements Business - The company owns several brands, including Doctor's Best and Zipfizz, with production services provided by its U.S. subsidiary, VitaBest [4] - Sales of Doctor's Best and Zipfizz experienced a decline in the first half of 2025 due to inventory control and purchasing adjustments by downstream customers [5] - The company is focusing on brand building and enhancing marketing efforts to improve sales channels and brand influence [5] Group 5: Domestic Nutritional Supplements Business - The domestic market for nutritional supplements is primarily served through online channels like Tmall and JD.com, with growth driven by the increasing demand for cross-border e-commerce [5] - The company aims to enhance operational efficiency and expand its market share in domestic self-owned brands [5]